Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach

Amber Tong

Vaccines. Antibodies. Antivirals. The Covid-19 pandemic has given the world a crash course on the key medical tools that can protect humans from viruses. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach

Amber Tong

Sign up to read this article for free.

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

New Trump era could be a boon for biopharma M&A, dealmaking

Biotech industry worries over potential for RFK Jr. ally as FDA pick

California voters say yes to restrictions around 340B spending

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Nasal sprays to stave off virus­es days at a time? J&J’s newest biotech part­ner draws $140M for 'proac­tive' ap­proach

Amber Tong

Sign up to read this article for free.

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Cal­i­for­nia vot­ers say yes to re­stric­tions around 340B spend­ing

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

New Trump era could be a boon for biopharma M&A, dealmaking

Biotech industry worries over potential for RFK Jr. ally as FDA pick

California voters say yes to restrictions around 340B spending

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks